Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heparin versus enoxaparin versus no post-PCI injectable anticoagulation after primary angioplasty for STEMI
IRCT20220809055645N4Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- May 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of heparin and enoxaparin in myocardial infarction (MI) and acute ST-segment elevation myocardial infarction (STEMI) (3 arms), sponsored by Guilan University of Medical Sciences. Primary endpoint: Composite of stroke, cardiac death, and recurrent myocardial infarction. Started May 2023; status: completed.
02
Drugs
heparinenoxaparin
03
Conditions
myocardial infarction (MI)acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on IRCT20220809055645N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220809055645N4.